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EARLY DIAGNOSIS OF PROSTATE
CANCER IN THE WESTERN CAPE
C F Heyns, A M· aude, A J Visser, D C Marais,
H B Stopforth, J K Nyarko, G A Stellmacher
Background. Early stage prostate cancer does not cause
symptoms, and even metastatic disease may exist for years
without causing symptoms or signs. Whereas early stage
prostate cancer can be cured with radical prostatectomy or
radiotherapy, the prognosis of patients with locally
advanced or metastatic cancer is significantly poorer.
Objectives. In view of the high incidence of advanced and
therefore incurable prostate cancer seen at the oncology
clinic of the Department of Urology, Tygerberg Hospital, we
started a prostate clinic with the aim of detecting early stage
prostate cancer which is potentially curable. A secondary
objective was to investigate the question whether there is a
higher incidence of prostate cancer among black African
men.
Patients and methods. Men aged 50 - 70 years were invited by
means of media communications (newspaper and radio) to
attend our prostate clinic for a free physical examination,
including a digital rectal examination (DRE) and serum
prostate specific antigen (PSA) assay. If the DRE was
clinically suspicious of malignancy and/or the serum PSA
was> 4 ng/ml, the patient was appropriately counselled
and referred for transrectal ultrasound (TRUS)-guided
sextant prostate biopsy.
Results. In the period June 1997 - September 1999 a total of
1 056 men attended the prostate clinic. Biopsies were
indicated in 160 cases, and were obtained in 114 (71.3%, i.e.
10.8% of the entire cohort). Prostate cancer was detected on
first biopsy in 3.5% of the entire group of men (in 35.9% of
those with a clinically abnormal DRE, in 41.3% of those
with a serum PSA > 4 ng/ml and in 88.6% of those with an
abnormal DRE and serum PSA > 4 ng/ml. In the 37 men
with prostate cancer, the clinical tumour stage was T1 - 2 in
83.8% and T3 - 4 in 16.2%. In the dOuP of patients with
clinical stage T1 - 2 tumours, the treatment was watchful
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waiting in 62.5% of cases, radiotherapy in 20.8% and radical
prostatectomy in 16.7%. Analysis of the data according to
race showed that in the group of 47 black men there was a
higher percentage of clinically abnormal DRE, PSA
> 4.0 ng/ml and biopsies showing malignancy, and a higher
overall prostate cancer detection rate (8.5%).
Conclusions. Our prostate cancer detection rate of 3.5% is
slightly lower than that reported in larger studies (4.7%),
which may be due to the fact that prostate biopsy was
performed in only 71% of those who had an indication for
biopsy. In the men diagnosed with clinically localised
prostate cancer, potentially curative treatment was given in
only 37.5% of cases. This compares unfavourably with the
historical cohort of men seen at our oncology clinic, where
53% received potentially curative treatment, and a large
European study where potentially curative treatment was
given in 89% of cases. Our finding that black men had a
higher percentage of clinically abnormal DRE, PSA
> 4.0 ng/ml and biopsies showing malignancy and a higher
overall detection rate of prostate cancer should be interpreted
with caution, since black men comprised only 4.5% of our
overall study cohort.
s Afr Med J2001; 91: 679-684.
Prostate cancer is the second most common histologically
diagnosed cancer in South African men, with an estimated
annual incidence of 19.1 per 100 000 men.' However, thi
incidence rate is probably deceptively low owing to incomplete
reporting of cases. Comparison of the incidence of prostate
cancer in the different racial groups shows that it is the second
most common histologically diagnosed malignancy in whites,
blacks and coloureds, and the fourth most common malignancy
in Asian (Indian) men in South Africa.' There have been several
studies suggesting that black (African) men may have a higher
incidence and a more aggressive type of prostate cancer, but
there are no published data from South Africa addressing these
questions.2~
Early stage prostate cancer does not cause symptoms, and
even metastatic disease may exist for years without causing
symptoms or signs. Whereas early stage (localised or
intracapsular) prostate cancer can be cured with radical
prostatectomy or radiotherapy, the prognosis for patients with
locally advanced (extracapsular) cancer is significantly poorer.
Once metasta es have occurred, the disease is no longer
curable and the median survival is in the range of 180 weeks,
despite the fact that approximately 0% of patients initially
respond well to endocrine treatment (androgen ablation)!
Two factors are highly predictive of survival in patients with
localised prostate cancer treated conservatively, namely tumour
histological features (especially grade), and patient co-
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morbidity.; Therefore, healthier men with a longer life
expectancy (around 10 years) may benefit from early detection
and treahnent. The incidence of prostate cancer in the USA has
ris·en dramatically, which is mainly explained by the increased
awareness and early detection activities." Recently, declines in
the incidence have been reported.7Furthermore, a decrease in
prostate cancer mortality in the USA has been observed, and
although there has been no clear explanation for this
phenomenon, the possibility that this trend is the result of early
detection and treahnent cannot be excluded.'
BACKGROUND
In the period 1976 - 1996, a total of 1 749 men "vith
histologically confirmed adenocarcinoma of the prostate were
seen at the oncology clinic of the Deparhnent of Urology at
Tygerberg Hospital.9Virtually all of these patients presented
because of symptoms related to prostatic disease. The majority
(77%) were between 61 and 80 years of age, with 51% over 70
years old. The race distribution was 51% coloured and Asian,
44% white and 5% black, compared with the race distribution
of the South African population as a whole, which comprises
approximately 69% black, 18% white, 11% coloured and 4%
Asian (Indian). This reflects the referral pattern to our hospital
over the past 20 years, and does not imply that prostate cancer
is less common in black men. However, it is not possible to
calculate accurately the incidence rate of prostate cancer in the
Western Cape since the denominator (total population of our
referral area) is not accurately known.
The tumour stage in the 1 749 men with prostate cancer seen
at our hospital between 1976 and 1996 was clinically localised
(Tl - 2) in 34% of cases, and locally advanced in 64% (T3 in 24%
and T4 in 42%).9 Localised tumours were more common in
white patients, while locally advanced tumours were more
common in coloured and black patients. Bone metastases
demonstrated by radio-isotope scintigraphy were present in
45% of the patients at presentation" This is similar to the
situation in the USA in 1982, before the era of screening, when
more than 40% of prostate cancer at the time of diagnosis was
locally advanced or metastatic. IO Even in a more recent survey
(1989 - 1994) carried out in the Netherlands during the era of
screening, it was found that among patients who presented
because of symptoms, 24% had metastases at the time of
diagnosis and 8% had locally advanced cancerY
The initial treatment in the cohort of 1 749 patients seen at
our oncology clinic was hormonal (mostly bilateral
orchidectomy) in 62%, radiotherapy in 21%, watchful waiting
(observational follow-up) in 16% and radical prostatectomy in
1%" Patients who could be considered potential candidates for
curative treahnent (stage Tlb - 2 MO tumours, patient under 70
years old) comprised only 13% of the entire cohort, since 66%
were stage T3 - 4 tumours and a further 21 % were stage T1a or
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M1 or patients over 70 years old. In those with potentially
curable disease (stage Tlb - 2 MO, age under 70 years), the
primary treahnent was radiotherapy in 42%, watchful waiting
in 39%, radical prostatectomy in 11% and hormonal (androgen
ablation) in 8% (Deparhnent of Urology, Tygerberg Hospital-
unpublished data, 1998).
Early detection of prostate cancer is possible, largely owing
to the identification of serum prostate-specific antigen (PSA),
which has proved to be the most powerful tool available for an
early diagnosis of prostate cancer.U In most studies the upper
limit of normal is accepted as 4.0 ng/ml, although some
authors have suggested that a lower cut-off level of 3.0 ng/ml
should be used.I'-I" Despite considerable inter-examiner
variability in the detection of prostate cancer by digital rectal
examination (DRE), the latter nonetheless significantly
increases the detection rate that can be achieved with PSA
alone. 17 Transrectal ultrasound (TRUS)-guided systematic
sextant (six core) biopsy of the prostate significantly increases
the ability to detect early prostate cancer, since it is superior to
random biopsies, even though the chance of missing tumour is
approximately 27%.1'.19
Data from large-scale randomised clinical trials of screening
for prostate cancer have shown that the screening tests are
generally well accepted, that 95% of all participants are willing
to be re-screened, and that TRU5-guided systematic sextant
biopsy of the prostate is a safe procedure for the diagnosis of
prostate cancer within the general population.20
OBJECTIVES
In view of the high incidence of advanced and therefore
incurable prostate cancer seen at our oncology clinic, we
started a prostate clinic in June 1997 with the aim of detecting
early stage prostate cancer which is potentially curable. A
secondary objective was to compare the prostate cancer
detection rates between race groups to address the question of
whether there is a higher incidence among black African men.
PATIE TS A D METHODS
Men were invited by means of media communications
(newspaper and radio) to attend the prostate clinic at the
Deparhnent of Urology, Tygerberg Hospital for a free physical
examination including a DRE and serum PSA assay. The target
group was asymptomatic men aged 50 - 70 years. The men
were seen by a registrar in urology and the assessment
consisted of the following: international prostate symptom
score (lPSS), urine dipstix analysis, blood taken for serum PSA
(Abbott IMX assay)!1 full medical history and physical
examination, including blood pressure and DRE. If the DRE
was clinically suspicious of malignancy and/or the serum PSA
was> 4 ng/ml, the patient was appropriately counselled and
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Fig. 1. Age distribution of men attending the prostate clinic.
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The patient data were recorded prospectively on a custom-
designed computer database (Access) and analysed with
statistical software available on Excel.
Statistics
referred for TRU5-guided sextant prostate biopsy. Patients were
given the options of having the biopsy performed at Tygerberg
Hospital or being referred to a private practising urologist of
their choice.
Biopsies were performed in an outpatient setting without
prior bowel preparation or cleansing enemas and without
anaesthesia. Aspirin or anticoagulant therapy was stopped 10
days before the biopsy, after consultation with -the subscribing
physician. Two hours before and 4 hours after the biopsy all
patients received oral antimicrobial therapy, usually
amoxycillin-clavulanic acid, ofloxacin or ciprofloxacin. TRUS
was performed using a 7 MHz-biplanar endorectal transducer.
Systematic sextant biopsies (six cores) were taken during
longitudinal scanning through an oblique channel in the
ultrasound probe using a Biopty or Magnum biopsy gun and
an 18-gauge (1.2 mm) biopsy needle. If a suspicious (hypo-
echoic) lesion was seen on TRUS, a biopsy was done through
the lesion.'"
Ethics
Prior approval for the study was obtained from the Ethical
Committee of the Faculty of Medicine, University of
Stellenbosch.
RESULTS
During the period June 1997 to September 1999 a total of 1 056
men attended the prostate clinic. Their median age was 60.6
years, and only 11% were older than 70 years (Fig. 1). The
mean and median IPSSs were 10 and 8, respectively. The IPSS
was ~ 5 in 38% of cases and 6 - 10 in 24%, therefore 62% of the
men had an IPSS ~ 10, indicating that the majority of patients
were relatively asymptomatic (Fig. 2). The race distribution
was 623 (59.5%) white, 337 (32.3%) coloured, 47 (4.5%) black
and 40 (3.8%) Asian.
The findings with regard to DKE, serum PSA and TRUS-
guided prostate biopsy are given in Table 1. Approximately
three biopsies were required to diagnose one prostate cancer.
The prostate biopsy results in subgroups of men are given in
Table IT.
In patients with histologically diagnosed benign prostate
hyperplasia (BPH), the mean free/total PSA ratio was 0.24,
median 0.20 and range 0.03 - 0.59, whereas in men with
histologically confirmed prostate cancer the mean free/total
PSA ratio was 0.17, median 0.15 and range 0 - 0.43. The
difference was statistically significant (P = 0.012, Student's t-
test).
Fig. 2. International Prostate Symptom Score (IPSS) for men
attending the prostate clinic.
In the 37 men with histologically confirmed prostate cancer,
the clinical tumour stage was T1 - 2 in 31 (83.8%) and T3 - 4 in
6 (16.2%). The treatment for 27 men (unknown in 10 patients)
was observational follow-up (watchful waiting) in 16 cases
(59.3%), radical prostatectomy in 5 (18.5%), radiotherapy in 5
(18.5%) and hormonal treatment in 1 (3.7%). In the group of 24
patients with clinical stage T1 - 2 tumours where the treatment
was known, it was watchful waiting in 15 (62.5%), radio-
therapy in 5 (20.8%) and radical prostatectomy in 4 (16.7%).
Analysis of the data according to race showed that in the
group of 47 black men there was a higher percentage of
clinically abnormal ORE, PSA > 4.0 ng/ml and biopsie
showing malignancy and a higher overall prostate cancer
detection rate, whereas the mean and median IPS was lower
than in the other race groups (Table lll).
DISCUSSIO
Although serum PSA is the most powerful tool for the
detection of early stage prostate cancer, it is not specific for
prostate cancer. Elevated PSA levels can be caused by BPH,
prostatitis, prostatic infarction, prostatic intra-epithelial
neoplasia (PIN) and perturbations of the prostate such as
biopsy or transurethral resection (TURP).22 Furthermore, not all
prostate cancers give rise to an elevated PSA.D
.
••
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Table I. Findings with regard to ORE, serum PSA and TRUS-guided prostate biopsy
N %of1 056 men % of subgroup
DRE clinically benign
DRE clinically malignant
DRE clinically suspicious
DRE not done or recorded
DRE abnormal (malignant + suspicious)
PSA> 4.0 ng/ml
DRE abnormal plus PSA > 4.0 ng/ml
DRE abnormal and/or PSA > 4.0 ng/ml
Preferred referral to private urologist
Prostate biopsies obtained
Prostate cancer on first biOpsy
Table IT. Prostate biopsy results in subgroups of men
964
32
49
11
81
102
35
160
41
114
37
91.3
3.0
4.6
1.0
7.7
9.7
3.3
15.2
10.8
3.5
25.6 (N = 160)
71.3 (N =160)
32.5 (N =114)
umber in subgroup
DRE clinically abnormal (%)
Serum PSA > 4.0 ng/ml (%)
Prostate biopsy performed (%)
Prostate cancer detected
(% of subgroup)
Prostate cancer detected
(% of entire cohort of 1 056)
DRE abnormal
81
22 (27.2)
53 (65.4)
19 (35.9)
19 (1.8)
PSA> 4.0 ng/ml
102
24 (23.9)
75 (73.5)
31 (41.3)
31 (2.9)
DRE abnormal +
PSA> 4.0 ng/ml
35
31 (88.6)
18 (58.1)
18 (1.7)
Table ITI. Comparison of findings in different race groups
White Coloured Black Asian
DRE abnormal (%) 8.2 6.6 12.8 2.6
PSA> 4.0 ng/ml (%) 9.3 7.7 21.3 15
Biopsies showing prostate cancer (%) 34.3 27.3 50 25
Incidence of cancer (%) 3.7 2.7 8.5 2.5
IPSSmean 9.6 10.8 7.2 12.0
IPSSmedian 7 8 6 10.5
The use of PSA and DRE will detect prostate cancer in
approximately 4% of subjects in a population-based screening
programme, but in a clinic population of symptomatic
urological patients detection rates up to 14.6% have been
described, showing that the detection rate is strongly
population dependent.'· Overall, in most screening studies
approximately 5 biopsies are needed to detect 1 carcinoma."; In
our study approximately 3 biopsies were required to diagnose
1 prostate cancer.
In a study of 31 953 eligible subjects screened in centres
throughout the USA, the prostate cancer detection rate for PSA
was 3.6%, for DRE 3.0%, and if both tests were positive it was
4.7%.14 The positive predictive value for an elevated PSA level
was 31.6%, whereas for DRE it was 25.5%. Overall, 31% of
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cancers were missed by DRE and diagnosed by PSA only, while
DRE detected 27.6% of cancers that would have been missed
by PSA. 14
In the European Randomised Study of Screening for Prostate
Cancer (ERSPC),26 10 865 men underwent a serum PSA
determination and in 1 368 cases (12.6%) the PSA level was
greater than 3.9 ng/ml.26 Biopsies were performed in 1 239
(90.6%) of these men and detected prostate cancer in 373
(30.2%), i.e. in 3.4% overall. In 2 619 men a biopsy was
indicated by either abnormal DRE and/or TRUS findings or a
serum PSA> 3.9 ng/ml. Biopsies were performed in 2 365
cases (90.3%), and cancer was detected in 505 (21.4%) men for
an overall cancer detection rate of 4.7%.26
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In our study the overall prostate cancer detection rate was
3.5%. The fact that this is somewhat lower than the 4.7% found
in larger studies may be due to the fact that prostate biopsies
were obtained in only 71% of our cases where they were
indicated, which is lower than the 90% biopsy rate in the
ERSPC study.26 Prostate cancer was found on the first biopsy in
32.5% of our patients, which is somewhat higher than the
21.4% in the ERSPC study.2. This may be due to somewhat
stricter selection criteria for prostate biopsy in our study, e.g. a
PSA cut-off of 4.0 ng/rnl instead of 3.9 ng/rnl.
In our study the lowest biopsy rate (65.4%) was in patients
who had only an abnormal ORE, whereas the highest biopsy
rate (88.6%) was in men with both an abnormal ORE and an
elevated PSA. This probably indicates reluctance on the part of
the physician to refer the patient for prostate biopsy solely on
the basis of an abnormal ORE. There is considerable inter-
examiner variability in ORE, indicating that experience plays
an important role in evaluation of the prostate by means of
ORE. Nonetheless, ORE significantly increases the detection
rate that can be achieved with PSA alone.17
In our study the positive predictive value (PPV) of an
elevated PSA for the presence of cancer on prostate biopsy
(41.3%) is higher than the 31.6% and 30.2% found in other
studies.14.26 In our study the PPV of an abnormal ORE was
35.9%, compared with 25.5% in a study from the USA.14 This
may be due to a greater reluctance in our study to obtain a
biopsy unless the PSA was significantly elevated or the ORE
was clearly abnormal. Our PPV for the combination of an
abnormal ORE plus elevated PSA was 58.1%, which confirms
the usefulness of combining ORE with PSA measurement, even
though in some European screening studies the use of ORE has
now been abandoned in favour of a lower PSA cut-off level of
3.2 ng/rnl.4
The question of re-screening men with an initially normal
PSA is still controversial. Re-screening at 6-monthly or yearly
intervals leads to a significant decrease in the prostate cancer
detection frequency (from 3% to less than 1%), and a 2-year
screening interval has been suggested for men with PSA levels
lower than 2 ng/mp.28 In patients with an indication for
prostate biopsy where no malignancy is found, a second
sextant biopsy within 6 months way reveal up to 23%
additional cases of prostate cancer.'" Therefore, in our study
follow-up of men with a negative first prostatic biopsy will
undoubtedly reveal more cases of cancer.
The racial distribution among men attending our prostate
clinic was white 59.5%, coloured plus Asian 36.1%, and black
4.5%. When compared with the racial distribution of men seen
at our oncology clinic (coloured plus Asian 51%, white 44% and
black 4%), the proportion of white patients attending ll-te
prostate clinic was higher. This probably reflects greater
awareness of prostate cancer and more favourable socio-
economic conditions in this population group (e.g. ac::ess to a
telephone, transport, ability to take time off from work to
attend the prostate clinic).
In our study black men had a higher percentage of clinically
abnormal ORE, PSA > 4.0 ng/rnl and biopsies showing
malignancy and a higher overall detection rate of prostate
cancer (Table Ill). The fact that the mean and median IPSSs
were lower in black patients than in the other race groups
seems to indicate that the higher detection rate of prostate
cancer was not due to the fact that these men sought
counselling because they were more symptomatic. However,
the lower IPSS score may also be due to a higher symptom
threshold, or to differences in the interpretation of the IPSS
questionnaire. Furthermore, these data have to be interpreted
with caution, since black men comprised only 4.5% of our
overall study cohort.
A major part of serum PSA occurs as a complex between PSA
and a1-antichymotrypsin (ACT). Patients with prostate cancer
have a significantly higher proportion of complexed PSA (PSA-
ACT) than those with BPH. Therefore, men with a relatively
low free/total PSA ratio are more likely to have cancer.'" The
free/total PSA ratio may be used to decrease the number of
biopsies in patients with an intermediate PSA of 4.0 - 10.0
ng/ml.25 Various cut-off levels for the free/total ratio have been
suggested, varying between 0.15 and 0.21, but cut-off values for
clinical practice have not yet been established.3I In our study
there was a statistically significant difference in the free/total
PSA ratio between those with and without prostate cancer on
biopsy. However, there was considerable overlap in the range
of free/total PSA values between the two groups. onetheless,
if there is doubt about the necessity for a prostate biopsy (e.g.
PSA marginally elevated, DRE suspicious but not clearly
abnormal), a free/total PSA ratio < 0.15 may be a strong
indicator that biopsy is indeed required.
The clinical stage distribution in 459 cases of prostate cancer
diagnosed in the Rotterdam section of the ERSPC tudy wa T1
in 25%, T2 in 52%, T3 in 20%, T4 in 1% and meta tatic to lymph
nodes or bone ( 1 or M1) in 2%.' Therefore, the cancer was
clinically localised in 77% of the patients in the ERSPC study,
which is comparable to the 83.8% of clinically localised
tumours found in our study.
However, a worrying a pect of our tudy is that in the men
diagnosed with clinically localised prostate cancer, the
treatment chosen was watchful waiting in 62.5% of cases,
radiotherapy in 20.8% and radical prostatectomy in 16.7%;
potentially curative treatment was therefore given in only
37.5% of cases. This is not much different from the historical .r.r:i~cohort of symptomatic men seen from 1976 to 1996 at our
oncology clinic, where patients with potentially curable early
stage disease were treated with radiotherapy in 42% of cases,
watchful waiting in 39%, radical prostatectomy in 11% and
hormonal treatment in 8%, i.e. 53% received potentially
curative treatment' In comparison, in the ERSPC study 38% of
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patients chose radical prostatectomy, 51% received
radiotherapy, watchful waiting was chosen by 8% and 2%
received endocrine therapy, i.e. potentially curative treatment
was given in 89% of cases.'
Many questions about the optimal treatment of early stage
prostate cancer remain controversial. Both radical
prostatectomy and radiotherapy (external beam or
brachytherapy) can cure the majority of patients with early
stage prostate cancer, but it is not clear which is the better
treatment, since no prospective, randomised comparisons have
been done. Recently, large randomised trials have been
initiated to compare radical prostatectomy and watchful
waiting in the management of early stage prostate cancer, but
their results will not be available for at least another decade.32.J3
However, with regard to quality-of-life issues, radical
prostatectomy is well accepted by at least 89% of patients who
have undergone this procedure, whereas watchful waiting has
been shown to increase anxiety among patients.3-l
Of 1 056 men who attended our prostate clinic for early
detection of prostate cancer, the majority were relatively
asymptomatic. Prostate cancer was found on the first biopsy in
3.5% of cases (with a possible higher incidence among black
men), and 84% of the men had potentially curable (early stage)
prostate cancer. However, in these men potentially curative
treatment was given in only 37.5% of cases, which compares
unfavourably with screening studies done in Europe and with
our own treatment of symptomatic patients seen over the last
20 years at Tygerberg Hospital, where curative treatment was
offered in 89% and 53% of cases, respectively.
Funding was provided by Abbott Laboratories (the latter also
provided the IMX assay kits for total and free PSA measurement),
the Freda and David Becker Trust, the Cancer Association of South
Africa, the Hayes Fund of the University of Stellenbosch and the
Department of Virology at Tygerberg Hospital where the PSA IMX
assays were performed. Mr P M de Beer, senior research technician
in the Department of Urology, also assisted with the PSA assays.
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